Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds

Overview

Journal Drug Metab Dispos

Specialty Pharmacology

Date 2017 Jul 13

PMID 28698302

Citations 4

Authors

Hsia-lien Lin

Haoming Zhang

Vyvyca J Walker

Jaime DAgostino

Paul F Hollenberg

Affiliations

Soon will be listed here.

Abstract

The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: -(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated. The loss of hydroxyebastine (OHEB) carboxylation activity in a reconstituted system was time- and concentration-dependent and required NADPH for MS and OD, but not DZ. The kinetic constants for the mechanism-based inactivation of OHEB carboxylation activity were: of 6.1 μM and of 0.22 min for MS and of 2.5 μM and of 0.05 min for OD. The partition ratios for MS and OD were ∼10 and ∼20, respectively. Inactivation of CYP2J2 by MS or OD resulted in a loss of the native heme spectrum and a similar decrease in the reduced CO difference spectrum. A heme adduct was observed in the MS-inactivated CYP2J2. The possible reactive metabolite which covalently modified the prosthetic heme was characterized by analysis of the glutathione conjugates formed by MS or OD following oxygenation of the ethynyl moiety. Liquid chromatography-mass spectrometry showed that inactivation by MS or OD did not lead to modification of apoprotein. Interaction of CYP2J2 with DZ produced a type II binding spectrum with a of 2.8 μM and the IC for loss of OHEB carboxylation activity was 0.18 μM. In conclusion, heme modification by MS and OD was responsible for the mechanism-based inactivation of CYP2J2. The results suggest that the ethynyl moiety of MS and OD faces the heme iron, whereas the isoxazole ring of DZ is preferentially oriented toward the heme iron of CYP2J2.

Citing Articles

Flipside of the Coin: Iron Deficiency and Colorectal Cancer.

Aksan A, Farrag K, Aksan S, Schroeder O, Stein J Front Immunol. 2021; 12:635899.

PMID: 33777027 PMC: 7991591. DOI: 10.3389/fimmu.2021.635899.

Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

de Montellano P Drug Metab Rev. 2019; 51(2):162-177.

PMID: 31203694 PMC: 6699906. DOI: 10.1080/03602532.2019.1632891.

Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2.

Lafite P, Andre F, Graves J, Zeldin D, Dansette P, Mansuy D Int J Mol Sci. 2018; 19(7).

PMID: 30012976 PMC: 6073854. DOI: 10.3390/ijms19072066.

Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17-Ethynylestradiol.

Lin H, Zhang H, Hollenberg P Drug Metab Dispos. 2018; 46(6):813-822.

PMID: 29602797 PMC: 5931439. DOI: 10.1124/dmd.118.080903.

References

Kent U, Lin H, Mills D, Regal K, Hollenberg P . Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol. 2006; 19(2):279-87. PMC: 2533710. DOI: 10.1021/tx050256o. View

Seubert J, Zeldin D, Nithipatikom K, Gross G . Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 2006; 82(1-4):50-9. PMC: 2077836. DOI: 10.1016/j.prostaglandins.2006.05.017. View

Lin H, Zhang H, Noon K, Hollenberg P . Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein. J Pharmacol Exp Ther. 2009; 331(2):392-403. PMC: 2775271. DOI: 10.1124/jpet.109.158782. View

Nithipatikom K, Brody D, Tang A, Manthati V, Falck J, Williams C . Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci. 2010; 101(12):2629-36. PMC: 3398840. DOI: 10.1111/j.1349-7006.2010.01713.x. View

Liu K, Kim M, Lee D, Yoon Y, Kim M, Shon J . Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006; 34(11):1793-7. DOI: 10.1124/dmd.106.010488. View

CaJacob C, Chan W, Shephard E, Ortiz de Montellano P . The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids. J Biol Chem. 1988; 263(35):18640-9. View

Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H . Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther. 2001; 300(1):298-304. DOI: 10.1124/jpet.300.1.298. View

Smith H, Jones 3rd J, Kalhorn T, Farin F, Stapleton P, Davis C . Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics. 2008; 18(11):943-53. PMC: 2709795. DOI: 10.1097/FPC.0b013e32830e1e16. View

Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottee L . Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos. 2009; 37(7):1528-38. DOI: 10.1124/dmd.109.027011. View

10.

Wang M, Zand B, Nguyen X, Falck J, Balu N, Schwartzman M . Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther. 1998; 284(3):966-73. View

11.

Yang B, Graham L, Dikalov S, Mason R, Falck J, Liao J . Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol. 2001; 60(2):310-20. DOI: 10.1124/mol.60.2.310. View

12.

Lafite P, Andre F, Zeldin D, Dansette P, Mansuy D . Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry. 2007; 46(36):10237-47. PMC: 2377029. DOI: 10.1021/bi700876a. View

13.

Lin H, Hollenberg P . The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J Pharmacol Exp Ther. 2007; 321(1):276-87. DOI: 10.1124/jpet.106.117861. View

14.

Seubert J, Yang B, Bradbury J, Graves J, Degraff L, Gabel S . Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res. 2004; 95(5):506-14. DOI: 10.1161/01.RES.0000139436.89654.c8. View

15.

Zeldin D, Foley J, Ma J, Boyle J, Pascual J, Moomaw C . CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol. 1996; 50(5):1111-7. View

16.

Jiang J, Shen G, Chen C, Fu X, Wang D . Effects of cytochrome P450 arachidonic acid epoxygenases on the proliferation of tumor cells. Ai Zheng. 2009; 28(1):14-9. View

17.

Zou A, Ma Y, Sui Z, Ortiz de Montellano P, Clark J, Masters B . Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid omega-hydroxylase, on renal function in rats. J Pharmacol Exp Ther. 1994; 268(1):474-81. View

18.

Falck J, Schwartzman M . Selective inhibition of arachidonic acid epoxidation in vivo. J Physiol Pharmacol. 2001; 51(4 Pt 1):655-72. View

19.

Lafite P, Dijols S, Buisson D, Macherey A, Zeldin D, Dansette P . Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett. 2006; 16(10):2777-80. PMC: 1876728. DOI: 10.1016/j.bmcl.2006.02.004. View

20.

Lin H, DAgostino J, Kenaan C, Calinski D, Hollenberg P . The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. Drug Metab Dispos. 2013; 41(10):1813-24. PMC: 3781371. DOI: 10.1124/dmd.113.053108. View